Palisade Bio Inc
PALI
Market Cap$77.26M
Close$
$13.61
125.7% upside
Current Fair Value
125.7% upsideUndervalued by 125.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $77.26 Million |
|---|---|
| Enterprise Value | $70.70 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-4.07 |
| Beta | 0.0 |
| Outstanding Shares | 12,771,015 |
| Avg 30 Day Volume | 2,829,345 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.04 |
|---|---|
| PEG | 10.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 9427.16 |
| Enterprise Value to EBIT | -6.5 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Palisade Bio Inc
7 employees
CEO: I. Richard Garr Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB114...